SANGAMO THERAPEUTICS, INC (SGMO)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenues | 18,306 | 6,437 | 49,412 | 356 |
| Research and development | 27,084 | 26,006 | 27,732 | 24,223 |
| Impairment of long-lived assets | - | - | - | 1,172 |
| General and administrative | 9,077 | 10,059 | 11,049 | 12,045 |
| Total operating expenses | 36,161 | 36,065 | 38,781 | 37,440 |
| Loss from operations | -17,855 | -29,628 | 10,631 | -37,084 |
| Interest income | 386 | 309 | 129 | 1,030 |
| Other (expense) income, net | -2,490 | -1,159 | - | - |
| Loss before income taxes | -19,959 | -30,478 | 10,760 | -36,054 |
| Income tax expense | 27 | 119 | 88 | 74 |
| Net loss | -19,986 | -30,597 | 9,385 | -36,128 |
| Net income allocated to participating securities | - | - | 1,287 | - |
| Net income (loss) available to common stockholders | - | - | 9,385 | - |
| Basic net loss per share (in dollars per share) | -0.08 | -0.14 | 0.05 | -0.18 |
| Diluted net loss per share (in dollars per share) | -0.08 | -0.14 | 0.04 | -0.18 |
| Shares used in computing basic net loss per share, (in shares) | 256,950,000 | 220,269,000 | 208,345,000 | 203,946,000 |
| Shares used in computing diluted net loss per share, (in shares) | 256,950,000 | 220,269,000 | 214,325,000 | 203,946,000 |